Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case–controlled study (ENIGI)

E Van Caenegem1,2, K Wierckx1,2, Y Taes1, T Schreiner2,3, S Vandewalle1, K Toye1, B Lapauw1, J-M Kaufman1 and G T’Sjoen1,2,4

1Department of Endocrinology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium, 2European Network for the Investigation of Gender Incongruence (ENIGI), Ghent, Belgium, 3Department of Endocrinology, Rikshospitalet, Oslo University Hospital, Sognsvannv 20, Oslo, Norway and 4Center for Sexology and Gender Problems, Ghent University Hospital, De Pintelaan 185, Ghent, Belgium

Abstract

Purpose: To assess the evolution of body composition and bone metabolism in trans men during the first year of cross-sex hormonal therapy.

Methods: In a prospective controlled study, we included 23 trans men (female-to-male trans persons) and 23 age-matched control women. In both groups, we examined grip strength (hand dynamometer), biochemical markers of bone turnover (C-terminal telopeptides of type 1 collagen (CTX) and procollagen 1 aminoterminal propeptide (P1NP)), total body fat and lean mass, and areal bone mineral density (aBMD) by dual-X-ray absorptiometry (DXA) and fat and muscle area at the forearm and calf, bone geometry, and volumetric bone mineral density (vBMD) by peripheral quantitative computed tomography (pQCT), before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks).

Results: Before hormonal treatment, trans men had similar bone and body composition compared with control women. Testosterone treatment induced in trans men a gain in muscle mass (10.4%) and strength and loss of fat mass (9.7%) (all P<0.001) and increased the levels of P1NP and CTX (both P<0.01). Areal and volumetric bone parameters remained largely unchanged apart from a small increase in trabecular vBMD at the distal radius and in BMD at the total hip in trans men (P=0.036 and P=0.001 respectively). None of these changes were observed in the control group.

Conclusions: Short-term testosterone treatment in trans men increased muscle mass and bone turnover. The latter may rather reflect an anabolic effect of testosterone treatment rather than bone loss.

Introduction

The importance of sex steroids in bone health is widely accepted, although the differential effects of estrogen and testosterone individually remain a topic of discussion. In the late 1990s, Riggs et al. (1) described a pivotal role for estrogen in the female and male skeleton. Recent research, assessing bone architecture, has questioned this model. Cortical bone loss still seems related with estrogen deficiency, but trabecular bone loss occurs earlier in adulthood, in both men and women, in the presence of normal sex steroid status, indicative that trabecular bone loss is either (partly) estrogen-independent or requires higher levels for its preservation (2, 3). Hence, quantitative computed tomography (QCT) and visualizing bone geometry can contribute for unraveling the interactions of sex steroid with trabecular and cortical bone. Sex steroids also influence bone size: men develop larger...
periosteal (outer) and endosteal (inner) circumference than women, partly due to the interplay of sex steroids, mechanical loading, and the growth hormone (GH)/insulin-like growth factor 1 (IGF1)-axis during puberty (4, 5, 6). In adulthood, periosteal apposition continues, but at a slower rate in women than in men (7). Sex steroid reversal, as encountered in trans men on testosterone treatment, may shed light on the role of individual contributions of sex steroids in the sexual dimorphism in bone geometry. Trans men have a female birth sex but identify as, or desire to be, a member of the male gender. In the case of gender dysphoria, this incongruence causes discomfort or distress often leading to the choice for testosterone treatment and/or sex reassignment surgery (SRS, including hysterectomy/salpingo-oophorectomy and mastectomy) (8). We previously reported a substantially higher muscle mass and a larger periosteal and endosteal circumference, higher trabecular volumetric bone mineral density (vBMD) and lower cortical vBMD in a cross-sectional study using peripheral QCT (pQCT) in adult trans men after long-term testosterone treatment (10 years) and SRS compared with age-matched control women (9). This larger bone size was probably mostly explained by the higher androgen-induced muscle mass in trans men (10, 11, 12, 13). In order to explore the direct and indirect (through increased muscle mass) influence of sex steroids on adult bone metabolism, mass, and size, we have set up a prospective controlled study in trans men, before any hormonal treatment compared with age-matched healthy control women. We evaluated body composition, bone turnover, volumetric (using pQCT), and areal bone parameters (using dual-X-ray absorptiometry (DXA)) in control women and trans men before and after the first year of testosterone therapy.

**Subjects and methods**

**Study design and population**

All trans men were diagnosed with gender dysphoria (DSM-5, 302.85; ICD-10, F64.0) and were recruited from the Center for Sexology and Gender Problems at the Ghent University Hospital, Belgium. All were treated following the World Professional Association for Transgender Health standards of care (8). This research is part of the ‘European Network for the Investigation of Gender Incongruence’ (ENIGI), a collaboration of four major West European gender identity clinics (Amsterdam, Ghent, Hamburg, and Oslo), a study group created to obtain more transparency in diagnostics and treatment of gender dysphoria (14).

Between February 2010 and October 2012, 30 trans men were included in the study. After screening by thorough medical history and determination of serum sex steroids, seven of them were excluded because of: past or present use of androgens substitution therapy (n = 2), anorexia nervosa in the past (n = 2), cerebral palsy (n = 1), refusal of bone densitometry (n = 1), and other treatment protocol (n = 1). In total, 23 trans men who had never used any kind of cross-sex hormonal treatment and, thus before SRS, were included. All participants were Caucasian. A female control population was recruited (n = 23), matched for age (± 2 years, median 1 year). These were women responded on posters spread at the Ghent University sites, Ghent University Hospital, and on its website.

All participants were in good physical health and completed questionnaires about previous illness and medication use, current and past smoking habits, and physical activity by recording the weekly frequency of sports, recreational, and/or working activities (using Baecke’s questionnaire (15)). Gynecological history was obtained in both trans men and control women and history of menstrual irregularities, hirsutism, or polycystic ovarian syndrome (PCOS) and the use of oral contraceptives (at baseline) were additional exclusion criteria for control women. Two trans men had a history of PCOS. Nine trans men used progestagens at baseline. The trans men and control women were evaluated after 1 year. In trans men, structured clinical visits were conducted at 3, 6, and 9 months. Trans men who used progestagens before the baseline study visit had similar baseline bone turnover, bone parameters, and body composition compared with trans men who did not (data not shown).

This data are part of a large prospective study (ENIGI), at the time of this analysis, 23 trans men had completed the 1-year follow-up. Three control women were no longer interested and did not complete the 1-year follow-up. All trans men received injections with i.m. testosterone undecanoate of 1000 mg (Nebido; Bayer), sometimes preceded by progestagens to suppress the menstrual cycle. Injections were administered at baseline, after 6 and 18 weeks, and from then once every 12 weeks. In case of nontolerance, injections with i.m. testosterone esters, every 2 weeks (testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone fenylopropionate 60 mg, and testosterone propionate 30 mg/ml) (Sustanon 250; Aspen, Dublin, Ireland) were prescribed (n = 1). Nine trans men had undergone SRS before the study visit at year 1. The changes in body composition, markers of bone turnover, and bone parameters were similar in trans men.
who underwent SRS during the first year of follow-up and those who did not (data not shown).

None of the subjects used vitamin D or calcium supplements or bone-active drugs (e.g. bisphosphonates) before the first study visit. In trans men with vitamin D insufficiency (<20 ng/ml; n=9), vitamin D supplements were prescribed. At year 1, only two subjects still used the vitamin D supplements. The study protocol was approved by the ethics review board of the Ghent University Hospital, registered with clinicaltrials.gov (identifier: NCT01072825), and all participants gave written informed consent.

Biochemical determinations
Venous blood samples were obtained between 0800 and 1000 h after overnight fasting. All samples were stored at −80 °C until analysis.

Testosterone and estradiol (E2) were determined by liquid chromatography-mass spectrometry (LCMS/MS) on an AB Sciex 5500 triple-quadrupole mass spectrometer (AB Sciex, Toronto, ON, Canada) (16). Commercial immunoassays were used to determine the serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), C-terminal telopeptides of type 1 collagen (CTX) (bone resorption) (Modular, Roche Diagnostics), procollagen 1 aminoterminal propeptide (P1NP) (bone formation) (Cobas 411, Roche Diagnostics), and IGF1 (Cisbio bioassays, Codolet, France). The intra assay coefficients and interassay coefficients of variation (CV) for all assays were <10%.

Body composition, muscle strength, and areal bone mineral density
Body weight and anthropometrics were measured in light indoor clothing without shoes. Standing height was measured using a wall-mounted Harpenden stadiometer (Holtain, Ltd, Crymuch, UK). The waist circumference was defined as the abdominal circumference located in the middle between the lower rib and the iliac crest and the hip circumference as the widest circumference around the buttocks.

Grip strength at the dominant hand was measured using an adjustable hand-held standard grip device (JAMAR hand dynamometer, Sammons and Preston, Bolingbrook, IL, USA). A maximum strength of three attempts was assumed to best reflect the current status and history of their musculoskeletal adaptation and was expressed in kilograms.

Body fat and lean mass, bone mineral content (BMC), projected bone area and areal bone mineral density (aBMD) at the whole body, lumbar spine, nondominant forearm, and left proximal femur (total hip and femoral neck region) were measured by DXA using a Hologic Discovery device (Software Version 11.2.1, Hologic, Inc., Bedford, MA, USA). The CV for both spine and whole-body calibration phantoms was <1%, as calculated from daily and weekly measurements respectively.

Volumetric bone parameters and cross-sectional muscle and fat area
A pQCT device (XCT-2000, Stratec Medizintechnik, Pforzheim, Germany) was used to evaluate the cortical vBMD and bone geometry at the dominant midshaft radius and tibia (at 66% of bone length) and trabecular vBMD at the metaphysis (at 4% of bone length) of the distal radius at the dominant side and cross-sectional muscle and fat area (at 66% of bone length). The details of procedure were as described previously (17). Scannings with large movement artifacts (distal radius: n=1, midshaft radius: n=3, and midshaft tibia: 3) and suspected position error (>10% variation of total bone area at distal radius: n=3, midshaft radius: n=9, and midshaft tibia: n=2) were excluded.

Statistical analyses
Descriptives were expressed as mean and s.d. or median (1st–3rd quartile) when criteria for normal distribution were not fulfilled. Comparison of general, anthropometric, biochemical, and hormonal determinations between trans men and age-matched controls were made using an independent sample t-test (or Mann–Whitney U test, when criteria for normal distribution were not fulfilled). In order to adjust for height, multiple regression analysis was used to compare bone and body composition in trans men compared with control women at baseline. The models included height and treatment group (trans men or control women) as independent variables. The interaction term of treatment group with visit is shown (comparison over time). P values <0.05 were considered
Table 1 General characteristics, hormones, and bone turnover markers in control women and trans men before and after 12 months. Descriptives are expressed as mean ± S.D. or as median (1st–3rd quartile) when not normally distributed.

<table>
<thead>
<tr>
<th></th>
<th>Control women (n=23)</th>
<th>Trans men (n=23)</th>
<th>Baseline comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>27 ± 9</td>
<td>27 ± 9</td>
<td></td>
</tr>
<tr>
<td>Pack year</td>
<td>0 (0–0)</td>
<td>0 (3–4)</td>
<td>†</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>66.8 ± 7.7</td>
<td>65.5 ± 14.5</td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>168.5 ± 5.7</td>
<td>163.3 ± 4.3</td>
<td>†††</td>
</tr>
<tr>
<td>Fracture prevalence (%)</td>
<td>35</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Parity (%)</td>
<td>30</td>
<td>17</td>
<td>†</td>
</tr>
<tr>
<td>Sport index</td>
<td>2.9 ± 1.0</td>
<td>3.3 ± 1.5</td>
<td></td>
</tr>
<tr>
<td>Leisure time index</td>
<td>3.3 ± 0.7</td>
<td>2.6 ± 0.8</td>
<td>†</td>
</tr>
<tr>
<td>Work index</td>
<td>2.3 ± 0.6</td>
<td>2.9 ± 0.7</td>
<td>††</td>
</tr>
<tr>
<td>Total physical activity</td>
<td>8.5 ± 1.5</td>
<td>8.9 ± 2.2</td>
<td></td>
</tr>
<tr>
<td>Testosterone (ng/dl)</td>
<td>31 ± 12</td>
<td>27 ± 12</td>
<td></td>
</tr>
<tr>
<td>E2 (pg/ml)</td>
<td>57 (43–124)</td>
<td>54 (24–110)</td>
<td></td>
</tr>
<tr>
<td>LH (U/l)</td>
<td>8 (5–14)</td>
<td>5 (4–8)</td>
<td>†</td>
</tr>
<tr>
<td>FSH (U/l)</td>
<td>7 (5–8)</td>
<td>4 (3–8)</td>
<td>†††</td>
</tr>
<tr>
<td>25-OH vitamin D (ng/ml)</td>
<td>25 ± 12</td>
<td>19 ± 11</td>
<td></td>
</tr>
<tr>
<td>P1NP (μg/l)</td>
<td>63 ± 36</td>
<td>62 ± 34</td>
<td></td>
</tr>
<tr>
<td>CTX (ng/ml)</td>
<td>0.46</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.33–0.68)</td>
<td>(0.27–0.65)</td>
<td></td>
</tr>
</tbody>
</table>

Baseline comparison: all variables were adjusted for height. *Using χ²-test. †Following Baecke 1982 (15), ††Detection limit LH-assay = 0.1 U/L. †††Detection limit FSH-assay = 0.1 U/L. Parity: % of participants who gave birth. The baseline comparison (third column) is adjusted for height, the P-value for the group (control women or trans men) is given by †P<0.05, †††P<0.001. The comparison over time (last column) is performed by an ANOVA for repeated measurements with group (trans men or control women), visit (baseline or 12 months), and height as independents; P-value for visit×group, **P<0.01, and ***P<0.001.

to be statistically significant, all tests were two-tailed. Data were analyzed using SPSS Software, version 21 (SPSS, Inc.).

Results

Baseline comparison

Trans men and control women had a median age of 27 years (range 18–47 years; Table 1). Both groups had comparable weight and BMI, though trans men had shorter stature than control women. The group of trans men comprised more active and smokers 26% vs 9% and more ex-smokers 35% vs 14% (Fisher’s exact test: P=0.038) and the amount of pack years was higher. Total testosterone and E2 were comparable in both groups. LH was slightly lower in trans men (range 1–31) compared with (range 1–50) control women (Table 1).

Trans men and control women had similar measures of fat and muscle mass and strength (Table 2). Waist-to-hip ratio was significantly higher in trans men, possibly due to a lower hip circumference.

Areal BMD (Table 3), trabecular and cortical vBMD, cortical bone size (Table 4), and bone turnover markers (Table 1) were comparable in trans men and control women at baseline; however, trabecular vBMD at the radius seemed slightly higher in trans men (nonsignificant).

Follow-up after 1-year of testosterone therapy

In trans men, serum testosterone increased and E2 levels decreased significantly and both were within the normal male ranges at year 1 (Table 1). We observed a 10.4% increase in lean body mass and 9.7% decrease in total body fat mass during the first year of testosterone treatment in trans men (vs +0.7 and +5.9% in control women during 1 year follow-up) in the presence of unchanged BMI and waist and hip circumference. Similar trends were observed at the peripheral limbs and this increase in muscle mass was reflected by a higher grip strength after testosterone treatment (+18.2%). Other changes in body composition is given in Table 2.

Markers of bone formation, especially P1NP, markedly increased during the first year of treatment in trans men, whereas no changes over time were noted in control women (Table 1).

Short-term evaluation of areal and volumetric parameters showed a largely unchanged status apart from a
modest gain of aBMD at the total hip and of trabecular 
vBMD at the distal radius in trans men (Table 3). No changes were recorded in cortical vBMD or bone size over time and/or between groups (Table 4).

**Discussion**

In this prospective controlled study, we showed that testosterone therapy in trans men induced changes in body composition including a gain in lean body mass, muscle mass, and strength. Bone turnover markers increased significantly during the first year of testosterone treatment in trans men.

The increased muscle mass and loss of fat mass are consistent with previous research carried out in trans men using testosterone treatment (10, 11, 12, 13) and confirm the anabolic effects of testosterone on skeletal muscle described in men (18).

A rise in bone formation marker in trans men has been reported during the first 2 years of testosterone treatment (11, 19) and higher bone formation markers were observed in trans men after long-term testosterone treatment vs control women (9). The latter long-term study also demonstrated higher serum levels of bone resorption markers, which is in agreement with the current results (9). However, not all studies in trans men documented higher bone resorption (11, 19, 20). Furthermore, our observations on areal bone parameters correspond with previous research reporting a preservation of aBMD during the first years of testosterone treatment (11, 12, 13, 21, 22) as well as after a longer exposure time and SRS (up to 10 years) in trans men (19, 20, 23). Some studies even reported a higher aBMD at cortical sites (femoral neck (9, 21), whole-body and tibial diaphysis (20)) and cortical thickness (iliac crest (24)) as well as greater bone size (larger periosteal and endosteal circumference of the radius) (9) in trans men compared with control women. The currently observed modest rise in aBMD at the total hip in a short-term may be in line with these results. Though the current bone data may be preliminary, the small gain in trabecular vBMD confirms our earlier cross-sectional research showing higher values in trans men on long-term testosterone treatment compared with control women (9).

We hypothesize that the increased bone turnover and discrete increases in aBMD at the total hip and trabecular vBMD may be due to the indirect effects of testosterone therapy. Following the mechanostat theory, the considerable increase in muscle mass imposes a higher strain on bone which stimulates higher bone modeling and remodeling (25). Indeed, muscle mass constitutes one of the main triggers in periosteal bone formation during puberty (6, 25, 26), and a beneficial effect of structured exercise in premenopausal women on femoral neck and lumbar spine aBMD was demonstrated in a recent

---

**Table 2** Body composition in control women and trans men before and after 12 months. Descriptives are expressed as mean ± s.d. or as median (1st–3rd quartile) when not normally distributed.

<table>
<thead>
<tr>
<th></th>
<th>Control women (n=20)</th>
<th>Trans men (n=23)</th>
<th>Baseline comparison</th>
<th>Control women (n=20)</th>
<th>Trans men (n=23)</th>
<th>Comparison over time: time×group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>23.7±3.0</td>
<td>24.5±5.3</td>
<td></td>
<td>24.1±3.5</td>
<td>25.2±4.1</td>
<td>2.1 3.9</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>72.2±6.5</td>
<td>78.4±14.2</td>
<td></td>
<td>74.0±10.0</td>
<td>78.2±11.3</td>
<td>2.6 0.5</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>100.3±7.0</td>
<td>91.1±7.9</td>
<td></td>
<td>99.3±9.1</td>
<td>98.4±7.4</td>
<td>−0.9 0.5</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.7±0.0</td>
<td>0.8±0.1</td>
<td>†</td>
<td>0.8±0.1</td>
<td>0.8±0.1</td>
<td>4.5 1.1</td>
</tr>
<tr>
<td>Total body – fat mass (kg)</td>
<td>19.3±6.1</td>
<td>19.9±8.7</td>
<td></td>
<td>20.0±7.3</td>
<td>17.5±6.7</td>
<td>5.9 9.7</td>
</tr>
<tr>
<td>Total body – fat mass (%)</td>
<td>28±6</td>
<td>29±7</td>
<td></td>
<td>29±7</td>
<td>25±6</td>
<td>3.4 13.6</td>
</tr>
<tr>
<td>Trunk fat mass (kg)</td>
<td>7.3 (4.7–11.0)</td>
<td>6.5 (5.2–10.7)</td>
<td></td>
<td>6.4 (4.7–10.7)</td>
<td>6.5 (4.5–9.9)</td>
<td>6.8 4.4</td>
</tr>
<tr>
<td>Fat CSA forearm (cm²)</td>
<td>13 (10–14)</td>
<td>12 (9–17)</td>
<td></td>
<td>14 (11–15)</td>
<td>11 (8–15)</td>
<td>2.5 10.8</td>
</tr>
<tr>
<td>Fat CSA calf (cm²)</td>
<td>28 (23–30)</td>
<td>29 (22–34)</td>
<td></td>
<td>28 (22–33)</td>
<td>25 (19–29)</td>
<td>1.6 12.9</td>
</tr>
<tr>
<td>Total body – lean mass (kg)</td>
<td>45.4±3.1</td>
<td>43.5±6.9</td>
<td></td>
<td>46±4.1</td>
<td>47.7±6.1</td>
<td>0.7 10.4</td>
</tr>
<tr>
<td>Total body – lean mass (%)</td>
<td>68±6</td>
<td>67±6</td>
<td></td>
<td>68±7</td>
<td>72±6</td>
<td>−1.3 6.5</td>
</tr>
<tr>
<td>Grip strength (N/kg)</td>
<td>32±4</td>
<td>30±6</td>
<td></td>
<td>31±4</td>
<td>35±5</td>
<td>−1.2 18.2</td>
</tr>
<tr>
<td>Muscle CSA forearm (cm²)</td>
<td>28±3</td>
<td>29±5</td>
<td></td>
<td>28±3</td>
<td>34±5</td>
<td>0.2 16.6</td>
</tr>
<tr>
<td>Muscle CSA calf (cm²)</td>
<td>68±8</td>
<td>64±12</td>
<td></td>
<td>70±8</td>
<td>73±13</td>
<td>1.2 13.6</td>
</tr>
</tbody>
</table>

CSA, cross-sectional area. Baseline comparison: all variables were adjusted for height. The baseline comparison (third column) is adjusted for height, the P value for the group (control women or trans men) is given by *P<0.05. The comparison over time (last column) is performed by an ANOVA for repeated measurements with group (trans men or control women), visit (baseline or 12 months) and height as independents: P value for visit×group, *P<0.01, and ***P<0.001.
meta-analysis (27). In some of these trials, the training indeed promoted bone formation (28). A second indirect action of testosterone can be through the aromatization in estrogens. Estrogens also affect bone size and may interact with mechanical loading (6).

The anabolic effect of testosterone on female body composition and bone metabolism is further supported by research in women with endogenous hyperandrogenism and postmenopausal women on testosterone therapy. A higher regional muscle mass (29), higher trabecular vBMD (30, 31), and aBMD at the lumbar spine (32, 33) as well as larger cortical bone size (31) and aBMD at cortical sites (whole body (32, 34) and femoral neck (33)) were described in women with endogenous hyperandrogenism and/or hirsutism. Similarly, exogenous testosterone added to hormonal replacement therapy in postmenopausal women resulted in higher lean body mass and muscle mass (35, 36) and increased hip (35, 37) and spine aBMD (35, 38) after 2 years compared with estrogen treatment alone.

Furthermore, higher muscle mass and strength have indeed been positively associated with trabecular vBMD in women (39, 40, 41) and a higher trabecular number and/or thickness have been related with higher appendicular muscle mass in women (41). Men develop thicker trabeculae during puberty (3, 4, 42) and we might presume that testosterone treatment in trans men led to the acquisition of thicker trabeculae and consequently higher measured trabecular vBMD similar to that young males compared with females. High resolution pQCT and longer follow-up are however needed to explore the trabecular microarchitecture of trans men. Furthermore, the trabecular vBMD seemed higher in trans men before treatment, compared control women, therefore baseline differences cannot be ruled out. Trans men might have participated more in sports during puberty, leading to higher trabecular vBMD (43).

In addition to effects on BMD, sex steroid exposure appears to affect bone size (6). During puberty, men develop larger bone size partly due to the interplay of sex steroids with mechanical loading (6, 44), and positive relationships of testosterone with periosteal circumference have been observed in pubertal boys and young men (5, 6, 45). The current results cannot confirm the previously reported larger radial cortical bone size and thinner cortex in trans men after 10 year of testosterone treatment compared with control women (9), although the observation time was probably too short to detect changes.
In our previous study, the observed bone phenotype in trans men under treatment was likely driven by changes in body composition, but the direct effects of testosterone on bone, in particular trabecular bone (6), and bone metabolism in trans men could not be ruled out (9). Using a multivariate statistical modeling, differences in both trabecular and cortical vBMD between trans men on long-term testosterone therapy and control women remained significant after adjusting for grip strength (9).

Secondly, testosterone can also act indirectly through estrogen aromatization. The effect of estrogen in male bone, especially bone geometry.

Our study has several limitations. Owing to the rarity of the condition, the sample size is small with implications for statistical power. Also, some trans men already used progestagens before the start of the study. The lower baseline LH at baseline is possibly due to the use of progestagens, but bone turnover and bone parameters at baseline were similar when compared with those who did not use this treatment. Further, trans men were significantly shorter than control women and female Belgian standards (mean height for Belgian women: 166.6 cm) (46). This difference has been previously reported, though its origin and significance are unknown (47). All tests on bone and body composition were, however, adjusted for height and yielded similar results as those of the unadjusted tests. Furthermore, although areal and volumetric bone changes can be detected during a 12-month follow-up (48, 49), the follow-up period might have been too short to detect bone geometry changes. Long-term follow-up is ongoing. The strengths of our study are the design and methods. Furthermore, we lack information on nutritional calcium intake, which may be relevant in the interpretation of the bone data (50). Trans men also smoked more and had lower vitamin D levels, which may be detrimental for bone (51). Bone parameters at baseline were comparable with control women. Cross-sex hormonal treatment in trans men provides a unique opportunity to observe the differential effects of sex steroids on genetically female bone. We use a prospective controlled design, which has, to our knowledge, not been reported in trans persons allowing the differentiation of changes due to aging or treatment. LCMS/MS was used for the determination of sex steroids, which has the required sensitivity for assay of low ranges of E2, as found in trans men on testosterone therapy (16).

### Conclusion

One year of testosterone treatment induced a higher muscle mass and lower fat mass in trans men, as well as higher bone turnover and modest increases in trabecular vBMD and aBMD. This may reflect the anabolic effects of testosterone on the female bone metabolism, possibly mediated by the higher strain on bone exerted by the androgen-induced increase in muscle mass.

#### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
This work was supported in part by Grant G.0867.11 from the Research Foundation Flanders. Eva Van Caenegem, Sara Vandewalle, and Katrien Wierckx are holders of a PhD fellowship from respectively the Research Foundation Flanders (Eva Van Caenegem and Sara Vandewalle) and Ghent University (Katrien Wierckx). This research support from Bayer and from the European Society for Sexual Medicine (Grant for Preclinical and Clinical Research 2012).

Acknowledgements
The authors are indebted to Griet De Cuyperere, MD, PhD; Gunter Heylens, MD, PhD; Els Elaut, MSc; Birgit Van Hoorde, MSc; Steven Weyers, MD, PhD; Piet Hoebeke, MD, PhD; Stan Monstrey, MD, PhD for referral of participants; and to Jens Jacobet, MD (MVZ Praxis im Chilehaus, Hamburg, Germany) and Mick van Trotsenburg, MD (Vrije Universiteit, Amsterdam, The Netherlands) for their contribution in the development of the ENIGI endocrinological protocol. They thank all volunteers who participated as study subjects. They also thank Veronique Van den Bossche and Kathelyne Mertens for their excellent technical assistance.

References


